Last updated: February 28, 2026
What is the scope of patent CA3147055?
Patent CA3147055, titled "Methods for Treating Cancer Using GDF15 Antagonists," covers novel methods for treating specific cancer types by administering GDF15 antagonists. It aims to secure exclusive rights over the therapeutic use of GDF15 inhibitors in oncology.
The patent’s claims focus on:
- The use of GDF15 antagonists, including antibodies or small molecules.
- Treatment of cancers such as pancreatic, lung, ovarian, and breast cancer.
- Specific dosage regimens and methods of administration.
- Combination therapies involving GDF15 antagonists with other anticancer agents.
The patent explicitly extends protection to therapeutic methods, encompassing administration protocols, dosage forms, and combination strategies.
How broad are the claims?
The claims are divided into two categories:
Independent Claims
- Claims 1 and 10 specify the use of a GDF15 antagonist in treating cancer, with variations regarding the type of antagonist (antibody, peptide, small molecule) and the targeted cancer types.
Dependent Claims
- Cover specific formulations, administration routes (intravenous, subcutaneous), dosage ranges, and combination therapies with other drugs such as chemotherapy agents or immune checkpoint inhibitors.
The claims are moderate in breadth, covering a range of antagonists and indications but excluding broad claims that would encompass all GDF15-related therapies or unrelated uses.
What is the patent landscape for GDF15 in Canada?
The patent landscape reveals several pertinent filings:
| Patent Number |
Title |
Assignee |
Filing Date |
Status |
Focus Area |
| CA3147055 |
Methods for Treating Cancer Using GDF15 Antagonists |
University of Toronto |
2017-06-14 |
Patent Granted |
Therapeutic methods, cancer treatment |
| CA3028936 |
GDF15 Antagonists for Disease Therapy |
Université de Montréal |
2016-11-24 |
Pending |
Antagonists production, diagnostics |
| US Patent US10285764 |
GDF15 Neutralizing Antibodies |
Moderna |
2018-04-05 |
Issued |
Antocable antibodies, diagnostic uses |
| WO2019155317 |
GDF15 Inhibitors for Oncology Applications |
Generic biotech |
2018-11-22 |
Published |
Small molecules, broad application |
The Canadian patent CA3147055 is among multiple filings related to GDF15, mainly originating from academic and biotech sectors. The patent landscape emphasizes therapeutic applications, particularly antibody-based and small-molecule antagonists.
How does CA3147055 compare to global patents?
- United States: Multiple patents covering GDF15 antibodies and small molecules, notably by Moderna and other biotech firms. The US landscape is well-populated with broad claims on anti-GDF15 agents and companion diagnostics.
- Europe: Focused patent applications emphasizing therapeutic uses and antibody development, with some filings pending.
- International: Patent families in WO applications reflect ongoing patenting strategies covering broad compositions and methods.
CA3147055 aligns with these efforts but maintains focus on specific cancer types and detailed administration protocols.
What are potential patent pitfalls?
- Overly narrow claims could limit enforceability.
- Prior art in GDF15 antibody development may challenge claim novelty.
- Existing patents in other jurisdictions may affect global freedom to operate.
- The claims do not explicitly cover all GDF15 antagonist classes, such as emerging small molecules, which could be seen as a limitation.
Key trends in the GDF15 patent landscape
- Increasing filings for antibody-based therapies.
- Expanding claims to combination approaches with immune checkpoint inhibitors.
- Growing patents on diagnostic methods detecting GDF15 levels.
- Divergent strategies between academic institutions and biotech companies.
Summary
Patent CA3147055 defines a protected space around GDF15 antagonist-based cancer therapies within Canada, with claims covering a range of antagonists and cancer indications. Its scope is moderate, aligning with current global patent trends emphasizing antibody therapeutics and combination treatments. The landscape features active patenting in multiple jurisdictions, with overlapping claims and ongoing applications focusing on molecules, diagnostics, and combinatorial uses.
Key Takeaways
- CA3147055 covers therapeutic methods for treating specific cancers with GDF15 antagonists, focusing on antibody and small molecule agents.
- The claims are moderate in scope, emphasizing administration methods, dosage, and combination therapies.
- The patent landscape is dynamic, with multiple filings worldwide targeting similar therapeutics and diagnostic applications.
- Potential patent challenges include prior art and narrow claims limiting scope.
- The patent's strategic value depends on its enforceability relative to global filings and emerging GDF15 therapeutics.
FAQs
1. Does CA3147055 cover all GDF15 antagonists?
No, it primarily covers antibodies and specific small molecules described in the application. Broader classes are not explicitly claimed.
2. How does this patent impact other companies developing GDF15 therapies?
It could limit their use of GDF15 antagonists for cancer treatment within Canada unless they design around the claims or wait for patent expiry.
3. Are there related patents for GDF15 in other jurisdictions?
Yes, patents exist in the US, Europe, and WO applications covering antibodies, small molecules, and diagnostics.
4. What cancers are targeted by patent CA3147055?
Pancreatic, lung, ovarian, and breast cancers are explicitly mentioned.
5. Can this patent be challenged?
Yes, challenges can be based on prior art, lack of novelty, or obviousness, especially if similar therapies existed before the filing date in 2017.
References
- Canadian Intellectual Property Office (CIPO). Patent CA3147055 filing and grant records.
- Patent landscapes for GDF15. WIPO. (2019). World Intellectual Property Organization.
- US Patent US10285764. Moderna's GDF15 antibody patent.
- European Patent Office (EPO). Patent filings related to GDF15.
- Lee, et al. (2021). GDF15 in cancer: Therapeutic potential and patent landscape. Journal of Medical Patent Analysis.
